Tirzepatide, developed by Eli Lilly, is a synthetic peptide that activates both GLP-1 and GIP receptors
Conclusion The formulation could potentially be an one-month sustained-release injectable therapy with the expectation of anti - obesity effect
More on this topic Many doctors worldwide have voiced concerns about the drugs
The demand for effective weight loss treatment options has skyrocketed in recent years
Distinct from conventional approaches, Chinese medicine is characterized by its diverse mechanisms of action and reduced toxicity, supporting its application as either an adjunctive or primary therapeutic strategy
In some of those cases, patients have said they were not warned that taking Mounjaro may increase their risk of stomach paralysis (gastroparesis), bowel obstructions, or other adverse events